Healthcare Realty Trust raises 2026 normalized FFO guidance

By Reuters News


Overview

  • US medical office REIT reported Q3 net loss per share of $0.05 and normalized FFO per share of $0.42

  • Company raised 2026 normalized FFO and same store cash NOI growth guidance

  • Company repurchased 4.2 mln shares and renewed $500 mln buyback authorization


Outlook

  • Company raises 2026 Normalized FFO guidance to $1.65-$1.67 per share

  • Company lifts 2026 Same Store Cash NOI growth guidance to 5.00%-5.25%

  • Company says 2026 guidance reflects assumptions on rental rates, occupancy, and interest rates


Result Drivers

  • SAME STORE NOI - Co reported 5.1% same store cash NOI growth, with tenant retention at 88% and average cash leasing spreads of 8.6%

  • LEASING ACTIVITY - Co executed 1.5 mln sq ft of new and renewal leases in Q3, with average annual rent escalators of 3.1%

  • ACQUISITIONS - Co acquired $211 mln of assets in strategic JV with KKR since last quarter


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.05

Q3 Adjusted FFO Per Share

$0.42


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the specialized reits peer group is "buy."

  • Wall Street's median 12-month price target for Healthcare Realty Trust Inc is $22.00, about 25.5% above its October 28 closing price of $17.53


Reuters Recommended Reads

  • Oct 27 - Ventas Q3 normalized FFO per share rises 10% on senior housing strength

  • Oct 26 - Welltower Q3 normalized FFO per share rises 25%, guidance raised

  • Oct 27 - Universal Health Realty Income Trust Q3 profit rises, helped by lower interest costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.